vorinostat has been researched along with Carcinoma, Hepatocellular in 36 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 9.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| "Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and particularly for those who are unsuitable to receive life-prolonging transarterial chemo-embolization." | 7.80 | Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. ( Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE, 2014) |
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 5.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| "Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and particularly for those who are unsuitable to receive life-prolonging transarterial chemo-embolization." | 3.80 | Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. ( Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE, 2014) |
| "To clarify whether histone deacetylase inhibitors histone deacetylase inhibitors (HDACIs) can sensitize hepatocellular carcinoma (HCC) cells to sorafenib treatment." | 3.80 | Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. ( Cui, LJ; Li, AJ; Ma, SL; Wu, B; Wu, MC; Yin, L; Yuan, H, 2014) |
| "However, the role of Rnd1 in hepatocellular carcinoma (HCC) progression remains unclear." | 1.48 | The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. ( Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD, 2018) |
| "ISAHA and SAHA were used to treat HepG2 hepatoma xenograft-bearing mice." | 1.42 | Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[18F]-fluorothymidine PET. ( Chan, PC; Chang, CA; Chang, CW; Chen, FD; Chiou, SH; Chou, LS; Ho, CH; Hwang, JJ; Lin, WJ; Liu, RS; Wang, HE; Wu, CY, 2015) |
| "Herein, we describe the pharmacokinetic optimization of a series of class-selective histone deacetylase (HDAC) inhibitors and the subsequent identification of candidate predictive biomarkers of hepatocellular carcinoma (HCC) tumor response for our clinical lead using patient-derived HCC tumor xenograft models." | 1.38 | Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. ( Cai, J; Chen, D; Chen, J; Chen, L; Chen, T; Feng, L; Guo, L; He, Y; Ji, Y; Jin, TG; Li, S; Liang, C; Lin, X; Liu, Y; Lu, X; Mei, J; Ning, Z; Pan, D; Pan, S; Peng, Z; Ren, S; Ren, Y; Rong, Y; Shan, S; She, J; Tang, G; Wang, Z; Wong, JC; Wu, X; Xu, C; Zhang, C; Zhang, M; Zhang, N; Zhang, W; Zhang, X; Zhang, Z; Zhao, R; Zhao, W; Zhou, M, 2012) |
| "Sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by SAHA may suggest new strategies for the treatment of liver tumours." | 1.35 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. ( Angileri, L; Carlisi, D; D'Anneo, A; Di Fazio, P; Emanuele, S; Lauricella, M; Santulli, A; Tesoriere, G; Vento, R, 2009) |
| "OSU-HDAC42 is a potent, orally bioavailable inhibitor of HDAC with a broad spectrum of antitumor activity that includes targets regulating multiple aspects of cancer cell survival." | 1.34 | Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. ( Chen, CS; Chen, TJ; Cheng, AL; Hung, JH; Kashida, Y; Kulp, SK; Lin, ZZ; Lu, YS; Tang, M; Wang, D; Wang, YC, 2007) |
| "Treatment for advanced stages of hepatocellular carcinoma (HCC) remains unsatisfactory." | 1.33 | The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. ( Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (19.44) | 29.6817 |
| 2010's | 21 (58.33) | 24.3611 |
| 2020's | 8 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, JC | 1 |
| Tang, G | 1 |
| Wu, X | 1 |
| Liang, C | 1 |
| Zhang, Z | 1 |
| Guo, L | 1 |
| Peng, Z | 1 |
| Zhang, W | 1 |
| Lin, X | 1 |
| Wang, Z | 1 |
| Mei, J | 1 |
| Chen, J | 2 |
| Pan, S | 1 |
| Zhang, N | 2 |
| Liu, Y | 2 |
| Zhou, M | 1 |
| Feng, L | 1 |
| Zhao, W | 1 |
| Li, S | 1 |
| Zhang, C | 3 |
| Zhang, M | 1 |
| Rong, Y | 1 |
| Jin, TG | 1 |
| Zhang, X | 1 |
| Ren, S | 1 |
| Ji, Y | 1 |
| Zhao, R | 1 |
| She, J | 1 |
| Ren, Y | 1 |
| Xu, C | 1 |
| Chen, D | 2 |
| Cai, J | 1 |
| Shan, S | 1 |
| Pan, D | 1 |
| Ning, Z | 1 |
| Lu, X | 1 |
| Chen, T | 1 |
| He, Y | 1 |
| Chen, L | 1 |
| Soh, CK | 1 |
| Goh, WH | 1 |
| Wang, H | 1 |
| Ling, Y | 1 |
| Gao, WJ | 1 |
| Ling, C | 1 |
| Liu, J | 1 |
| Meng, C | 1 |
| Qian, J | 1 |
| Liu, S | 1 |
| Gan, H | 1 |
| Wu, H | 1 |
| Tao, J | 1 |
| Dai, H | 1 |
| Zhang, Y | 2 |
| Zhai, S | 1 |
| Zhang, H | 1 |
| Chen, R | 1 |
| Wu, J | 1 |
| Ai, D | 1 |
| Tao, S | 1 |
| Cai, Y | 1 |
| Zhang, JQ | 1 |
| Wang, L | 1 |
| Liu, Q | 2 |
| Zhang, B | 3 |
| Wang, Y | 2 |
| Wang, X | 1 |
| Gou, S | 1 |
| Lu, Y | 1 |
| Lan, J | 1 |
| Chan, YT | 1 |
| Feng, Z | 1 |
| Huang, L | 1 |
| Wang, N | 1 |
| Pan, W | 1 |
| Feng, Y | 1 |
| Li, JY | 1 |
| Tian, T | 1 |
| Han, B | 1 |
| Yang, T | 1 |
| Guo, YX | 1 |
| Wu, JY | 1 |
| Chen, YS | 1 |
| Yang, Q | 1 |
| Xie, RJ | 1 |
| Zhu, Q | 1 |
| Hu, H | 1 |
| Zhu, H | 1 |
| Yang, B | 1 |
| He, Q | 1 |
| Yu, L | 1 |
| Zeng, S | 1 |
| Sanaei, M | 1 |
| Kavoosi, F | 1 |
| Pourahmadi, M | 1 |
| Hassan, YA | 1 |
| Helmy, MW | 1 |
| Ghoneim, AI | 1 |
| Liao, B | 2 |
| Sun, Q | 1 |
| Jiang, P | 1 |
| Li, YL | 1 |
| Zhang, NY | 1 |
| Hu, X | 1 |
| Chen, JL | 1 |
| Rao, MJ | 1 |
| Wu, LW | 1 |
| Li, QY | 1 |
| Yan, W | 1 |
| Qin, CD | 1 |
| Ma, DN | 1 |
| Zhang, SZ | 1 |
| Ren, ZG | 1 |
| Zhu, XD | 1 |
| Jia, QA | 1 |
| Chai, ZT | 1 |
| Wang, CH | 1 |
| Sun, HC | 1 |
| Tang, ZY | 1 |
| Tang, C | 1 |
| Du, Y | 1 |
| Liang, Q | 1 |
| Cheng, Z | 1 |
| Tian, J | 1 |
| Gordon, SW | 1 |
| McGuire, WP | 1 |
| Shafer, DA | 1 |
| Sterling, RK | 1 |
| Lee, HM | 1 |
| Matherly, SC | 1 |
| Roberts, JD | 1 |
| Bose, P | 1 |
| Tombes, MB | 1 |
| Shrader, EE | 1 |
| Ryan, AA | 1 |
| Kmieciak, M | 1 |
| Nguyen, T | 1 |
| Deng, X | 1 |
| Bandyopadhyay, D | 1 |
| Dent, P | 1 |
| Poklepovic, AS | 1 |
| Wang, YC | 2 |
| Yang, X | 1 |
| Xing, LH | 1 |
| Kong, WZ | 1 |
| Hsu, FT | 1 |
| Liu, YC | 1 |
| Chiang, IT | 1 |
| Liu, RS | 2 |
| Wang, HE | 2 |
| Lin, WJ | 2 |
| Hwang, JJ | 2 |
| Yuan, H | 1 |
| Li, AJ | 1 |
| Ma, SL | 1 |
| Cui, LJ | 1 |
| Wu, B | 1 |
| Yin, L | 1 |
| Wu, MC | 1 |
| Chan, PC | 1 |
| Wu, CY | 1 |
| Chou, LS | 1 |
| Ho, CH | 1 |
| Chang, CW | 1 |
| Chiou, SH | 1 |
| Chen, FD | 1 |
| Chang, CA | 1 |
| Yang, H | 1 |
| Lan, P | 1 |
| Hou, Z | 1 |
| Guan, Y | 1 |
| Zhang, J | 1 |
| Xu, W | 1 |
| Tian, Z | 1 |
| Di Fazio, P | 4 |
| Lingelbach, S | 1 |
| Schobert, R | 1 |
| Biersack, B | 1 |
| Liang, H | 1 |
| Chen, X | 1 |
| Srinivas, C | 1 |
| Swathi, V | 1 |
| Priyanka, C | 1 |
| Anjana Devi, T | 1 |
| Subba Reddy, BV | 1 |
| Janaki Ramaiah, M | 1 |
| Bhadra, U | 1 |
| Bhadra, MP | 1 |
| Kotantaki, P | 1 |
| Mosialos, G | 1 |
| Goto, K | 1 |
| Annan, DA | 1 |
| Morita, T | 1 |
| Li, W | 1 |
| Muroyama, R | 1 |
| Matsubara, Y | 1 |
| Ito, S | 1 |
| Nakagawa, R | 1 |
| Tanoue, Y | 1 |
| Jinushi, M | 1 |
| Kato, N | 1 |
| Kunnimalaiyaan, S | 1 |
| Sokolowski, K | 1 |
| Gamblin, TC | 1 |
| Kunnimalaiyaan, M | 1 |
| Carlisi, D | 3 |
| Lauricella, M | 3 |
| D'Anneo, A | 3 |
| Emanuele, S | 3 |
| Angileri, L | 1 |
| Santulli, A | 1 |
| Vento, R | 3 |
| Tesoriere, G | 3 |
| Liu, YL | 1 |
| Yang, PM | 1 |
| Shun, CT | 1 |
| Wu, MS | 1 |
| Weng, JR | 1 |
| Chen, CC | 1 |
| Zhang, JX | 1 |
| Li, DQ | 1 |
| He, AR | 1 |
| Motwani, M | 1 |
| Vasiliou, V | 1 |
| Eswaran, J | 1 |
| Mishra, L | 1 |
| Kumar, R | 1 |
| Hsieh, YH | 1 |
| Su, IJ | 1 |
| Yen, CJ | 1 |
| Tsai, TF | 1 |
| Tsai, HW | 1 |
| Tsai, HN | 1 |
| Huang, YJ | 1 |
| Chen, YY | 1 |
| Ai, YL | 1 |
| Kao, LY | 1 |
| Hsieh, WC | 1 |
| Wu, HC | 1 |
| Huang, W | 1 |
| Gray, SG | 1 |
| Qian, CN | 1 |
| Furge, K | 1 |
| Guo, X | 1 |
| Teh, BT | 1 |
| Ocker, M | 1 |
| Alajati, A | 1 |
| Ganslmayer, M | 1 |
| Zopf, S | 1 |
| Lüders, M | 1 |
| Neureiter, D | 1 |
| Hahn, EG | 1 |
| Schuppan, D | 1 |
| Herold, C | 1 |
| Vassallo, B | 2 |
| Venturelli, S | 1 |
| Armeanu, S | 1 |
| Pathil, A | 1 |
| Hsieh, CJ | 1 |
| Weiss, TS | 1 |
| Vonthein, R | 1 |
| Wehrmann, M | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Bitzer, M | 1 |
| Lu, YS | 1 |
| Kashida, Y | 1 |
| Kulp, SK | 1 |
| Wang, D | 1 |
| Hung, JH | 1 |
| Tang, M | 1 |
| Lin, ZZ | 1 |
| Chen, TJ | 1 |
| Cheng, AL | 1 |
| Chen, CS | 1 |
| Di Leonardo, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma[NCT01075113] | Phase 1 | 16 participants (Actual) | Interventional | 2010-08-10 | Completed | ||
| A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas[NCT01132911] | Phase 1 | 5 participants (Anticipated) | Interventional | 2010-05-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for vorinostat and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug I | 2019 |
35 other studies available for vorinostat and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Topics: Anilides; Animals; Biomarkers, Pharmacological; Carcinoma, Hepatocellular; Cell Line, Tumor; CpG Isl | 2012 |
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts | 2018 |
β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carbolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prol | 2019 |
Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoxazoles; Carcinoma, Hepatocellular; Cell Movement; C | 2021 |
Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
Topics: Acetylation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proli | 2022 |
Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.
Topics: Acetylation; Animals; Carcinoma, Hepatocellular; Histone Deacetylases; Histones; Humans; Liver Neopl | 2023 |
Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells.
Topics: Autophagy; Carcinoma, Hepatocellular; Cell Death; Histones; Humans; Liver Neoplasms; Lysine; Vorinos | 2023 |
Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
Topics: Acetylation; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dose-Response Relationship, | 2021 |
Effect of Decitabine (5-aza-2'-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-P
Topics: Antigens, Neoplasm; Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell S | 2021 |
Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines.
Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Pro | 2021 |
Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Carcinoma, Hepat | 2018 |
Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell | 2018 |
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genet | 2018 |
Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferati | 2020 |
Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Sh | 2013 |
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2014 |
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Protein | 2014 |
Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[18F]-fluorothymidine PET.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Disease Models, A | 2015 |
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Epigenomics; Hep G2 Cells; Histocompat | 2015 |
4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Histone Deacetylase I | 2015 |
Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2015 |
Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhi | 2016 |
The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines.
Topics: Butyric Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Deubiquitinating Enzyme CYLD; Gene Expres | 2016 |
Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Coculture Techniques; C | 2016 |
Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Cycle; Cell Line, Tumor; Cell Proli | 2017 |
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; CASP8 and FADD-Like | 2009 |
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, | 2010 |
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclic AMP; DNA Damage; Drug Resistance, Neo | 2012 |
Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Nucleus; Cell Pro | 2013 |
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.
Topics: Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Enzyme Inhibitors; Gene Expression Profiling; Gene | 2004 |
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; | 2005 |
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Car | 2007 |
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Hepatocellular; Cel | 2007 |
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Topics: Animals; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Disea | 2007 |
Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Benzothiazoles; Carcinoma, Hepatocellular; Cell Line, | 2008 |